BioSpace News Archive

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2020 financial results will be released after the markets close on Wednesday, May 13th

VIQ Solutions Inc. (“VIQ” or the “Company”) (TSX Venture Exchange: VQS and OTC Markets: VQSLF) a global provider of secure, AI-driven, digital voice and video capture technology and transcription services, today reported financial results for the first quarter 2020 and updated its 2020 outlook

Align Technology, Inc. (NASDAQ: ALGN) today announced the availability of virtual solutions that help doctors connect with existing Invisalign patients to ensure continuity of care

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today announced that the Company has entered into a definitive credit agreement with a syndicate of lenders agented by MidCap Financial Trust (“MidCap Financial”) in respect of a secured asset-based revolving credit facility having a term of 38 months (the “ABL Facility”).

FARAPULSE Inc. (“FARAPULSE” or “the Company”) and its pulsed field ablation (PFA) technology for Atrial Fibrillation featured heavily in the collection of science published online by the Heart Rhythm Society in lieu of an annual meeting.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported first quarter 2020 financial results and provided a business update.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2020.

In an effort to keep the communities of our clients and employees safe, ICONMA recently launched our COVID-19 Medical Screening Service

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the regulatory pathway for Vicinium in Europe.